Delivery Order SPE2DB20D7066-SPE2DB25FC4MB
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Adenosine 12 mg/4 mL syringes with a ceiling value of $1,183.83. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13,...
- The Defense Logistics Agency awarded a delivery order valued at $1,292.82 to AmerisourceBergen Drug Corp for the supply of Adenosine 12 mg/4 mL syringes on August 21, 2025, with completion scheduled for August 22, 2025. This contract, which carries no set-aside designation, was competitively awarded on a firm fixed-price basis and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a continuation of pharmaceutical supply support under...
- The Defense Logistics Agency awarded a delivery order valued at $3,091.99 to AmerisourceBergen Drug Corp for the supply of Adenosine 12 mg/4 mL syringes on August 22, 2025, with completion expected by August 25, 2025. This firm fixed-price delivery order is being fulfilled from the company's place of performance in Conshohocken, Pennsylvania, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Adenosine 12 mg/4 mL syringes with a ceiling value of $1,027.81. This non-competitive delivery order will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. The contract utilizes firm fixed pricing under a delivery order arrangement, representing a...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Adenosine 12 mg/4 mL vials with a ceiling value of $1,084.19. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and no set-aside designation was used in the award. The work will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $1,282.59 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Adenosine 6 mg/2 mL syringes (2 mL volume). This firm fixed-price delivery order, which represents a non-set-aside competitive award, is scheduled for ultimate completion on July 23, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Adenosine 12mg/4ml (10 units) on August 21, 2025. This firm fixed price delivery order, valued at $2,154.70, represents a competitively awarded, non-set-aside contract with a place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- This delivery order, valued at $3,878.46, awards AmerisourceBergen Drug Corp the supply of Adenosine 12mg/4mL in quantities of 10 units for the Defense Logistics Agency's Medical Supply Chain. The contract was competitively awarded without any set-aside designation on August 21, 2025, with the same date serving as the ultimate completion deadline. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply Adenosine 12 mg/4 ml syringes. The contract has a potential value of $1,701.42 and a period of performance through January 26, 2024. Amerisourcebergen Drug Corp is the prime contractor and does not have any major subcontractors identified. This delivery order is issued under a larger indefinite delivery contract...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a $1,136.88 delivery order to AmerisourceBergen Drug Corp for the supply of Adenosine 12 mg/4 mL vials on July 18, 2025, with completion targeted for July 21, 2025. The award utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC4MBDelivery Order
The Defense Logistics Agency awarded a $3,993.45 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Adenosine 12 mg/4 ml syringes. The contract, which is not set-aside and competitively awarded, represents a firm fixed price delivery order with an ultimate completion date of August 26, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's portfolio under the DLA Troop Support Medical IDC encompasses a broad range of pharmaceutical products and medical supplies, including specialty medications, generic and brand-name drugs, vaccines, and medical devices across multiple therapeutic domains. This specific delivery order for Adenosine—a critical cardiac and respiratory emergency medication—reflects the company's role in maintaining medical supply chain readiness for Defense Health Agency and broader federal healthcare customers on a global basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 8/25/25 |